PURPOSE: The purpose of this study was to assess the feasibility and sensitivity of the high-affinity translocator protein (TSPO) ligand [(123)I]-CLINDE in imaging TSPO changes in vivo and characterise and compare astroglial and TSPO changes in the cuprizone model of demyelination and remyelination in C57BL/6 mice. METHODS: C57BL/6 mice were fed with cuprizone for 4 weeks to induce demyelination followed by 2-4 weeks of standard diet (remyelination). Groups of mice were followed by in vivo single photon emission computed tomography (SPECT)/CT imaging using [(123)I]-CLINDE and uptake correlated with biodistribution, autoradiography, immunohistochemistry, immunofluorescence and real-time polymerase chain reaction (RT-PCR). RESULTS: The uptake of [(123)I]-CLINDE in the brain as measured by SPECT imaging over the course of treatment reflects the extent of the physiological response, with significant increases observed during demyelination followed by a decrease in uptake during remyelination. This was confirmed by autoradiography and biodistribution studies. A positive correlation between TSPO expression and astrogliosis was found and both activated astrocytes and microglial cells expressed TSPO. [(123)I]-CLINDE uptake reflects astrogliosis in brain structures such as corpus callosum, caudate putamen, medium septum and olfactory tubercle as confirmed by both in vitro and in vivo results. CONCLUSION: The dynamics in the cuprizone-induced astroglial and TSPO changes, observed by SPECT imaging, were confirmed by immunofluorescence, RT-PCR and autoradiography. The highly specific TSPO radioiodinated ligand CLINDE can be used as an in vivo marker for early detection and monitoring of a variety of neuropathological conditions using noninvasive brain imaging techniques.
PURPOSE: The purpose of this study was to assess the feasibility and sensitivity of the high-affinity translocator protein (TSPO) ligand [(123)I]-CLINDE in imaging TSPO changes in vivo and characterise and compare astroglial and TSPO changes in the cuprizone model of demyelination and remyelination in C57BL/6 mice. METHODS: C57BL/6 mice were fed with cuprizone for 4 weeks to induce demyelination followed by 2-4 weeks of standard diet (remyelination). Groups of mice were followed by in vivo single photon emission computed tomography (SPECT)/CT imaging using [(123)I]-CLINDE and uptake correlated with biodistribution, autoradiography, immunohistochemistry, immunofluorescence and real-time polymerase chain reaction (RT-PCR). RESULTS: The uptake of [(123)I]-CLINDE in the brain as measured by SPECT imaging over the course of treatment reflects the extent of the physiological response, with significant increases observed during demyelination followed by a decrease in uptake during remyelination. This was confirmed by autoradiography and biodistribution studies. A positive correlation between TSPO expression and astrogliosis was found and both activated astrocytes and microglial cells expressed TSPO. [(123)I]-CLINDE uptake reflects astrogliosis in brain structures such as corpus callosum, caudate putamen, medium septum and olfactory tubercle as confirmed by both in vitro and in vivo results. CONCLUSION: The dynamics in the cuprizone-induced astroglial and TSPO changes, observed by SPECT imaging, were confirmed by immunofluorescence, RT-PCR and autoradiography. The highly specific TSPO radioiodinated ligand CLINDE can be used as an in vivo marker for early detection and monitoring of a variety of neuropathological conditions using noninvasive brain imaging techniques.
Authors: Kate O'Brien; Denise C Fitzgerald; Karmeswaree Naiken; Kishore R Alugupalli; A M Rostami; Bruno Gran Journal: Curr Med Chem Date: 2008 Impact factor: 4.530
Authors: B Klem; G Lappin; S Nicholson; J van de Wetering; D E de Vries; B Oosterhuis; R C Garner Journal: J Clin Pharmacol Date: 2006-04 Impact factor: 3.126
Authors: P D Callaghan; C A Wimberley; G L Rahardjo; P J Berghofer; T Q Pham; T Jackson; D Zahra; T Bourdier; N Wyatt; I Greguric; N R Howell; R Siegele; Z Pastuovic; F Mattner; C Loc'h; M C Gregoire; A Katsifis Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-18 Impact factor: 9.236
Authors: Cornelius K Donat; Khaled Gaber; Jürgen Meixensberger; Peter Brust; Lars H Pinborg; Henrik H Hansen; Jens D Mikkelsen Journal: Neuromolecular Med Date: 2016-03-11 Impact factor: 3.843
Authors: Valerie L Jewells; Hong Yuan; Joseph R Merrill; Jonathan E Frank; Akhil Patel; Stephanie M Cohen; Ben Giglio; Nana Nikolaishvili Feinberg; Glenn K Matsushima; Zibo Li Journal: Diagnostics (Basel) Date: 2021-04-27
Authors: Craig P Motbey; Emily Karanges; Kong M Li; Shane Wilkinson; Adam R Winstock; John Ramsay; Callum Hicks; Michael D Kendig; Naomi Wyatt; Paul D Callaghan; Iain S McGregor Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240
Authors: Dianne E Lee; Xuyi Yue; Wael G Ibrahim; Margaret R Lentz; Kristin L Peterson; Elaine M Jagoda; Michael Kassiou; Dragan Maric; William C Reid; Dima A Hammoud Journal: J Neuroinflammation Date: 2015-09-17 Impact factor: 8.322
Authors: F Mattner; M Quinlivan; I Greguric; T Pham; X Liu; T Jackson; P Berghofer; C J R Fookes; B Dikic; M-C Gregoire; F Dolle; A Katsifis Journal: Dis Markers Date: 2015-06-25 Impact factor: 3.434